


The link between circulating follicular helper T cells and autoimmunity

Lucy S. K. Walker 

Abstract | Follicular helper T (T_{FH}) cells provide help to B cells, supporting the formation of germinal centres that allow affinity maturation of antibody responses. Although usually located in secondary lymphoid organs, T cells bearing features of T_{FH} cells can also be identified in human blood, and their frequency and phenotype are often altered in people with autoimmune diseases. In this Perspective article, I discuss the increase in circulating T_{FH} cells seen in autoimmune settings and explore potential explanations for this phenomenon. I consider the multistep regulation of T_{FH} cell differentiation by the CTLA4 and IL-2 pathways as well as by regulatory T cells and highlight that these same pathways are crucial for regulating autoimmune diseases. The propensity of infection to serve as a cue for T_{FH} cell differentiation and a potential trigger for autoimmune disease development is also discussed. Overall, I postulate that alterations in pathways that regulate autoimmunity are coupled to alterations in T_{FH} cell homeostasis, suggesting that this population may serve as a core sentinel of dysregulated immunity.

Coordinated interaction between different immune cells is crucial for the development of protective immunity. Nowhere is this more obvious than in the emergence of high affinity antibody responses, where carefully orchestrated contacts between dendritic cells (DCs), T cells and B cells culminate in a refined and long-lived antibody response. The critical go-between in this cellular trio is the follicular helper T (T_{FH}) cell that liaises first with the DC, before migrating to the B cell follicle for repeated interaction with B cells¹. Such T_{FH} cells bear a characteristic phenotype including expression of markers such as CXC-chemokine receptor 5 (CXCR5; which promotes homing to the B cell follicle), programmed cell death protein 1 (PD1), inducible T cell costimulator (ICOS) and the transcription factor BCL-6 (REF.²) (BOX 1). T_{FH} cells are classically found in secondary lymphoid organs with a small population of similar cells present in the blood (referred to as circulating T_{FH} (cT_{FH}) cells). Curiously, multiple studies have revealed that cT_{FH} cells are present at increased frequencies in many autoimmune diseases, including systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), Sjogren syndrome (SS), autoimmune thyroid diseases, myasthenia

gravis, type 1 diabetes (T1D) and multiple sclerosis (MS)³. Consistent with elevations in cT_{FH} cell numbers, autoantibodies are commonly associated with these conditions and their presence often precedes symptomatic disease.

In this Perspective, I discuss core mechanisms controlling T_{FH} cell differentiation and highlight that these same pathways are linked to the regulation of autoimmune disease. I also discuss the potential for infection to serve as a link between T_{FH} cells and autoimmunity. Overall, I postulate that regulation of T_{FH} cells and regulation of autoimmunity are tightly coupled, perhaps explaining why increases in cT_{FH} cell numbers are evident across multiple autoimmune diseases.

Discovery of cT_{FH} -like cells

In 2005, a seminal publication from Vinuesa et al. showed that mutant mice with dysregulated T_{FH} cell differentiation exhibited systemic autoimmunity⁴. The causative mutation in these animals mapped to the *Roquin* (*Rc3h1*) gene, the product of which repressed ICOS expression and negatively regulated T_{FH} cell differentiation. These sanroque mice exhibited lupus-like

pathology and robust development of T1D when crossed to a T cell receptor (TCR) transgenic mouse model. Impairing T_{FH} cell differentiation, by rendering sanroque mice heterozygous for BCL-6 or deficient for SLAM-associated protein (SAP, an adaptor protein required for T_{FH} cell–B cell interactions⁵), ameliorated the autoimmune phenotype, leading to reduced autoantibody production and decreased renal pathology⁶. These findings sparked interest in whether T_{FH} cell differentiation might be connected to lupus pathology in humans, leading to the demonstration that cells with a T_{FH} cell phenotype were elevated in the blood of patients with SLE⁷. Reports documenting cT_{FH} -like cells in numerous other autoimmune diseases rapidly followed (reviewed in REF.⁸).

The spotlight was then turned on the true identity of these blood-borne T_{FH} -like cells, specifically on their relationship to germinal centre (GC)-resident T_{FH} cells. Important work from the Ueno group revealed that circulating CD4⁺CXCR5⁺ T cells shared functional properties with T_{FH} cells from secondary lymphoid organs and could provide help to B cells via IL-21 production⁹. This led to the idea that blood-borne CD4⁺CXCR5⁺ T cells were a memory counterpart of lymphoid T_{FH} cells, and a substantial body of evidence has since emerged to support this view^{10–14}. Consistent with this notion, individuals with defects in GC formation due to deficiency in ICOS or CD40L, or a developmental block in B cell development (BTK deficiency), have fewer circulating CD4⁺CXCR5⁺ cells, and they are absent altogether from the cord blood of newborns^{15,16}. Of note, many T_{FH} cell markers are downregulated in the memory phase^{12,17–19}, perhaps explaining early controversies over the existence of a T_{FH} cell memory pool. Experiments involving the adoptive transfer of mouse T_{FH} cells into antigen-free hosts indicate that CXCR5 expression is least affected by the phenomenon of T_{FH} cell marker loss²⁰, suggesting it may be the most reliable marker for tracking cT_{FH} cells. Painstaking experiments in which cT_{FH} cells were purified from mouse blood revealed that these cells can home to secondary lymphoid tissues upon re-challenge and participate in GC reactions, providing direct evidence

Box 1 | Transcription factors controlling T_{FH} cell development

BCL-6 is an essential transcription factor for follicular helper T (T_{FH}) cell differentiation^{143–145}, and its repression of BLIMP1 is necessary¹⁴⁴ but not sufficient¹⁴⁶ for the T_{FH} cell fate. Other key transcription factors include MAF, which is upregulated by inducible T cell costimulator (ICOS) ligation¹⁴⁷, and BATF, which controls expression of BCL-6 and MAF^{148,149}. ASCL2 promotes early T_{FH} cell differentiation by upregulating the expression of genes such as CXCR5 (REF.¹⁵⁰), whereas repression of KLF2 expression is required to maintain the T_{FH} cell phenotype¹⁵¹. STAT proteins play a major role in influencing T_{FH} cell differentiation in response to cytokines: STAT5 inhibits T_{FH} cell differentiation following IL-2 exposure and, conversely, STAT3, STAT1 and STAT4 promote T_{FH} cell differentiation in response to cytokines such as IL-6, IL-21 and IL-12 (REFS^{81,152,153}).

of their functional capacity upon antigen re-encounter¹⁸. Thus, the consensus view is that T_{FH} cells have a circulating memory compartment that retains expression of CXCR5 and, to a variable extent, other T_{FH} cell markers and can be recalled to participate in the memory phase of humoral responses.

Somewhat unexpectedly, the majority of cT_{FH} cells do not seem to derive from

the GC environment itself. In fact, imaging studies have shown that, although GC T_{FH} cells frequently move between GCs, their egress to the circulation is rare²¹. Instead, it appears that circulating CXCR5⁺ cells arise mainly from T_{FH} cells that have not yet undergone sustained interaction with B cells. In line with this, the frequency of cT_{FH} cells appears undiminished in mice and humans that lack

SAP expression and consequently exhibit impaired T cell–B cell interactions²². The link between lymphoid tissue T_{FH} cells and cT_{FH} cells has been compellingly demonstrated both by mass cytometric comparison of blood and tonsillar tissue with dimensionality reduction approaches²³ and by vaccination studies showing that blood CD4⁺CXCR5⁺ICOS⁺PD1⁺ cells²⁴ or CD4⁺CXCR5⁺PD1^{hi} cells²⁵ are clonally related to lymph node GC T_{FH} cells. Overall, this suggests a model in which T_{FH} cells at the T cell–B cell border can give rise to both GC-resident T_{FH} cells and cT_{FH} cells that travel through efferent lymph to the blood (FIG. 1). Consistent with this, T cells with T_{FH} cell features can be detected in thoracic duct lymph of mice and humans, and treatment with the drug FTY720, which prevents lymph node exit, dramatically decreases cT_{FH} cells in both species^{18,26,27}.

Common pathways regulate T_{FH} cell differentiation and autoimmunity

T_{FH} cell differentiation and provision of help to B cells is a tightly controlled process. B cell tolerance relies heavily on restricting T cell help, in part because the developmental regulation of T cells is more stringent; nascent T cells are screened against self-antigens during their thymic development, with transcription factors, such as autoimmune regulator (AIRE), ensuring a broad representation of peripheral self-antigens. By contrast, peripheral self-antigens may be less available to B cells developing in the bone marrow, and it has been reported that around 20% of mature naive B cells exhibit low levels of self-reactivity²⁸. B cell antigen specificity is also prone to diversification within GCs, superseding any developmental constraints on self-reactivity. Thus, denying T cell help to self-reactive B cells is necessary to prevent the initiation of potentially damaging autoimmune humoral responses. Ensuring that T cell–B cell collaboration is tightly regulated is also important for optimal protective immunity (BOX 2).

In considering the mechanisms controlling T_{FH} cell differentiation, three core and interconnected pathways emerge involving cytotoxic T lymphocyte antigen 4 (CTLA4), regulatory T (T_{reg}) cells and IL-2. Curiously, these same pathways are well recognized for their ability to regulate autoimmunity. Below, I explore evidence indicating that these pathways control T_{FH} cell differentiation and highlight their connection to autoimmune disease susceptibility.




Fig. 1 | Blood-borne cT_{FH} cells are clonally related to their lymphoid counterparts. Follicular helper T (T_{FH}) cells classically reside in secondary lymphoid organs where they support germinal centre (GC) B cell responses; however, T cells with similar markers can be detected in the lymph and blood. These circulating T_{FH} (cT_{FH}) cells have a memory phenotype and do not depend on GCs as they can arise in the context of SLAM-associated protein (SAP) deficiency, which abrogates sustained T cell–B cell interactions²². However, they do require B cells, as cT_{FH} cell frequencies are greatly reduced in individuals with B cell deficiency¹⁶. Blocking lymph node exit, by treatment with FTY720, dramatically decreases cT_{FH} cells in mice and humans^{18,26,27}. Clonotype sharing reveals a developmental relationship between T_{FH} cells found in the GC and the blood^{24,25} and those found in the lymph and the blood²⁶, suggesting that T cell–B cell interactions at the T cell–B cell border give rise to both GC T_{FH} cells and cT_{FH} cells. It is possible that some GC T_{FH} cells enter the circulation from GCs but this is likely to be rare²¹. Follicular regulatory T (T_{FR}) cells also have circulating counterparts (cT_{FR}); however, these have an immature phenotype and differentiate from regulatory T cells without the requirement for contact with B cells¹⁶⁴.

CTLA4-mediated regulation of T_{FH} cells.

CTLA4 controls T cell CD28 costimulation and is a crucial regulator of T cell responses (BOX 3). Multiple lines of evidence pinpoint the CTLA4–CD28 axis as a key modulator of T_{FH} cell responses (BOX 3). In mice, genetic deficiency or antibody-mediated blockade of CTLA4 triggers spontaneous T_{FH} cell differentiation and GC formation²⁹. GCs that form following CTLA4 blockade are dependent on CD28 (REF.²⁹), consistent with the established role of CTLA4 in regulating CD28 engagement and the importance of the CD28 pathway for T_{FH} cells and GCs^{30,31}. Experiments with CD28 heterozygous mice revealed a relationship between the amount of CD28 engagement and propensity for T_{FH} cell differentiation²⁹, suggesting that CTLA4 may regulate this fate by policing access of CD28 to its ligands. CD28 likely promotes T_{FH} cell differentiation in multiple ways, including increasing ICOS expression, which drives strong phosphoinositide 3-kinase (PI3K) activation important for T_{FH} cell formation³², as well as regulating microRNAs implicated in T_{FH} cell fate^{29,33}.

There is also evidence that the CTLA4 pathway regulates T_{FH} cells in humans. Individuals deficient in LRBA, that show defective CTLA4 trafficking and function, exhibit increases in circulating T cells expressing T_{FH} cell markers (CXCR5 and PD1)³⁴. In addition, patients with cancer receiving anti-CTLA4 antibody immunotherapy show an increase in circulating T cells with T_{FH} cell markers (E. Ntavli, N. M. Edner and L.S.K. Walker, unpublished observations). Conversely, cT_{FH} cells are decreased following treatment with soluble CTLA4 molecules, such as the CTLA4–immunoglobulin fusion protein abatacept, in individuals with SS³⁵, RA³⁶, MS³⁷ or T1D³⁸. Thus, the CTLA4 pathway negatively regulates T_{FH} cell homeostasis in mice and humans, likely by restricting CD28 engagement.

CTLA4 and autoimmunity. The association between CTLA4 and autoimmunity is well documented. Genetic variation at the *CTLA4* locus is linked to numerous autoimmune diseases, including T1D, RA, SLE, myasthenia gravis, autoimmune thyroid diseases, coeliac disease, alopecia areata and vitiligo (see [GWAS Catalogue](#)). Mice genetically deficient for *Ctla4* develop lethal lymphoproliferation and multiorgan immune cell infiltration^{39,40}, and heterozygous *CTLA4* mutations in humans are associated with an immune dysregulation syndrome with multiple autoimmune

manifestations^{41,42}. Targeting the CTLA4 pathway by immunotherapy in patients with cancer can also elicit autoimmune side effects. CTLA4 function may be altered indirectly by mutations in genes encoding CTLA4 pathway regulators. For example, mutations in *LRBA* lead to reduced CTLA4 expression and autoimmune outcomes⁴³.

 T_{reg} cell-mediated control of T_{FH} cells.

T_{reg} cells express the transcription factor FOXP3 and play a crucial role in the maintenance of immune homeostasis. *Scurfy* mice, which lack functional T_{reg} cells owing to a frameshift mutation disrupting *Foxp3*, exhibit a marked expansion of BCL-6⁺CXCR5⁺ T_{FH} cells in secondary lymphoid tissues⁴⁴. Consistent with this, in mice expressing diphtheria toxin receptor under the control of the *Foxp3* promoter, short-term depletion of T_{reg} cells enhances the generation of antigen-specific T_{FH} cells in response to immunization^{45,46}. Similar to mice, patients with IPEX (immune dysregulation, polyendocrinopathy, enteropathy, X-linked) that have mutations in *FOXP3* also exhibit an increased frequency of CXCR5⁺PD1⁺ cT_{FH} cells⁴⁷. Thus, FOXP3⁺ T_{reg} cells appear to control T_{FH} cell numbers in both mice and humans.

T_{reg} cells constitutively express CTLA4. Interestingly, the enhanced T_{FH} cell differentiation associated with CTLA4 deficiency²⁹ can be recapitulated by loss of CTLA4 expression in T_{reg} cells alone^{45,48}. To avoid widespread immune dysregulation, Sage et al.⁴⁸ used mice in which tamoxifen-inducible *Foxp3*-Cre was used to excise the floxed *Ctla4* gene in T_{reg} cells immediately prior to immunization, whereas Wing et al.⁴⁵ probed the impact of partial loss of CTLA4 expression using heterozygous *Ctla4*-flox/wt mice expressing *Foxp3*-Cre. In both settings, increases in T_{FH} cells were observed after immunization. Collectively, these findings illustrate that T_{reg} cells are a non-redundant population mediating CTLA4-dependent regulation of T_{FH} cells.

The above observations could potentially reflect the role of CTLA4 in follicular regulatory T (T_{FR}) cells, the subset of T_{reg} cells that exhibit T_{FH} cell features and enter GCs^{44,46,49}. For T_{reg} cells to acquire the T_{FR} cell programme they downregulate CD25 (IL-2R α) expression, permitting them to express BCL-6, which would otherwise be antagonized by IL-2-driven BLIMP1 expression^{50,51}. T_{FR} cells are thought to optimize protective antibody responses while suppressing the generation of antibodies to self-antigens and allergens^{44,46,49,52–54} and, like T_{FH} cells, T_{FR} cells have a circulating counterpart that can be altered in autoimmunity^{55,56} (FIG. 1). Interestingly, selective depletion of T_{FR} cells, either in mice with floxed *Bcl6* and *Foxp3*-driven Cre expression^{54,57,58} or in mice with STOP-floxed *Cxcr5*-DTR and *Foxp3*-Cre⁵³, results in only minor or transient increases in T_{FH} cells despite marked effects on B cell differentiation. As loss of CTLA4 expression in FOXP3⁺ cells increases T_{FH} cells but loss of T_{FR} cells does not, it is possible that substantial CTLA4 activity occurs outside of the B cell follicle during the initial encounter between T cells and DCs. At the T cell–B cell border and within the follicle, T_{FR} cells may employ additional suppressive mechanisms such as expression of the neuropeptide neurtin⁵⁷ or targeting of B cell metabolic pathways⁵⁹.

In a fascinating twist, it appears that FOXP3-based regulation of T_{FH} cells can also operate in a cell-intrinsic manner. T_{FH} cells themselves upregulate FOXP3 expression in late-stage GCs, and this is associated with loss of expression of the T cell help-associated genes *IL21* and *CD40L* and GC collapse⁶⁰. These FOXP3⁺ T_{FH} cells express high levels of CTLA4 and are reminiscent of the CD25⁺ T_{FR} cells described by Wing et al.⁶¹, the transcriptional profiles of which place them equidistant between T_{FH} cells and activated T_{reg} cells. The division of labour between T_{reg} cells, T_{FR} cells and FOXP3⁺ T_{FH} cells will need to be dissected

Box 2 | Optimal germinal centre B cell selection relies on restricting follicular helper T cell numbers

Upon antigen engagement, B cells migrate to the T cell–B cell border in search of T cell help¹⁵⁴. Restricting the number of T cells available limits how many B cells can seed germinal centres (GCs)¹⁵⁵, reducing the number of clones exposed to hypermutation. T cell–B cell interactions at the T cell–B cell border support the extrafollicular response¹⁵⁶ and dysregulation of extrafollicular T cells may lead to autoimmunity¹⁵⁷. In the follicular response, B cells compete again for T cell help in the GC light zone, with those expressing the highest affinity receptors able to capture more antigen and present higher peptide concentrations. Immunoglobulin gene mutations resulting in enhanced antigen affinity trigger GC B cells to upregulate CCL22 and CCL17 expression, allowing them to preferentially attract T cell help¹⁵⁸. Limiting the number of T cells available and ensuring that their cytokine output remains 'stingy'¹⁵⁹ are crucial features of the competitive environment required for affinity maturation to occur.

by further experimentation. Taken together, T_{reg} cell populations play a key role in controlling T_{FH} cell numbers in both mice and humans, potentially via the CTLA4 pathway.

T_{reg} cells and autoimmunity. Many of the genes associated with susceptibility to autoimmunity are expressed in T_{reg} cells⁶² and the pre-eminent role for T_{reg} cells in regulating autoimmunity is well recognized. Mice lacking T_{reg} cells develop lethal autoimmunity⁶³ and humans with an impaired T_{reg} cell compartment as a result of mutations in *FOXP3* develop the aggressive early-onset immune dysregulation syndrome IPEX⁶⁴. Interestingly, deficits in T_{reg} cells can interfere with normal costimulatory control of T cell immunity — the unexpected exacerbation of disease in CD28-deficient non-obese diabetic mice was reconciled by the discovery of the role of CD28 in T_{reg} cell development⁶⁵, and recent findings suggest CD28 also contributes to T_{reg} cell homeostasis in humans⁶⁶. A replete T_{reg} cell compartment is therefore key to the normal regulation of immune responses, and strategies aimed at augmenting T_{reg} cell

numbers, by low-dose IL-2 treatment or T_{reg} cell therapy, are being actively pursued in settings of autoimmunity.

IL-2-mediated regulation of T_{FH} cells. The IL-2 pathway is recognized as a major regulator of T_{FH} cell differentiation (FIG. 2). In mice, exogenous provision of IL-2 has been shown to suppress T_{FH} cell differentiation both in the context of viral infection⁶⁷ and autoimmunity⁶⁸. In humans, IL-2 is also a known regulator of T_{FH} cell differentiation⁶⁹, and low-dose IL-2 therapy can decrease numbers of cT_{FH} cells in individuals with autoimmune disease⁷⁰.

One potential mechanism by which IL-2 inhibits T_{FH} cells is by enhancing T_{reg} cell homeostasis as IL-2 is a key cytokine for T_{reg} cell expansion and maintenance^{71–73}. However, it is clear that IL-2 can also act directly on conventional T cells to inhibit T_{FH} cell differentiation. During T cell priming, IL-2 signalling can alter the balance between T_{FH} cell and non- T_{FH} cell effector differentiation^{74,75} via STAT5-mediated skewing of the BLIMP1 to BCL-6 ratio^{76,77}. In an interesting twist, T cells induced to make IL-2 are not those that respond to

it — instead, the producers become T_{FH} cells while using IL-2 in a paracrine manner to preclude their neighbours from this fate⁷⁸. This finding establishes a biological role for the synaptic-based delivery of IL-2 between adjacent T cells undergoing activation⁷⁹.

Such is the threat to T_{FH} cell differentiation posed by IL-2 that a variety of mechanisms exists to subvert this inhibition. Transforming growth factor- β (TGF β) insulates T cells from IL-2 signals by suppressing CD25 (IL-2R α) expression⁸⁰, which may contribute to its ability to promote T_{FH} cell differentiation⁸¹. Activated DCs in the outer T cell zone upregulate CD25, allowing developing T_{FH} cells to approach the B cell follicle in an environment quenched of local IL-2 (REF.⁸²). Mature T_{FH} cells can be shielded from IL-2 in a different manner, becoming desensitized to IL-2 signalling via IL-6-mediated downregulation of the IL-2 receptor subunit CD122 (IL-2R β)⁸³. The local availability of IL-2 and other cytokines is therefore an important factor in controlling T_{FH} cell numbers. Intriguingly, in conditions of limiting IL-2, T helper 1 cells can increase their BCL-6 to T-bet ratio and assume a partial T_{FH} cell phenotype⁸⁴. Thus, some cells bearing T_{FH} cell markers in autoimmune settings could conceivably have arisen via this route.


The intersection between IL-2-mediated and T_{reg} cell-mediated control of T_{FH} cell differentiation is a complex one. T_{reg} cells might be expected to promote T_{FH} cell differentiation by serving as an IL-2 sink^{85,86} but they can also limit T_{FH} cell formation by CTLA4-dependent regulation of costimulation^{29,45,48}. One way to view this is that avoiding IL-2 signals may be necessary but not sufficient for T_{FH} cell differentiation and, as highlighted above, this can be achieved through a variety of means. By contrast, there seems to be little redundancy in control of CD28 costimulation, with CTLA4-expressing T_{reg} cells being required to restrict T_{FH} cell numbers^{45,48}. Thus, in the absence of T_{reg} cells, the effects of dysregulated CD28 costimulation may dominate over the lack of IL-2 consumption as other populations can compensate for the latter.

IL-2 and autoimmunity. The IL-2 pathway is strongly implicated in susceptibility to autoimmune disease. Single nucleotide polymorphisms (SNPs) in *IL2RA* are associated with multiple autoimmune diseases, including T1D, RA, IBD, MS, Crohn's disease, alopecia areata and vitiligo (see GWAS catalogue). In addition to *IL2RA* SNPs⁸⁷, autoimmune-associated variants have been identified in *IL2*, *IL2RB* and

Box 3 | CTLA4 function

Cytotoxic T lymphocyte antigen 4 (CTLA4) acts as a competitive inhibitor for the T cell costimulator CD28 as both receptors bind to the same ligands, CD80 and CD86, but CTLA4 binds with higher affinity. Furthermore, CTLA4 and CD80 form high-avidity dimer–dimer interactions¹⁶⁰. CTLA4 can function in a cell-extrinsic manner to remove CD80 and CD86 from antigen-presenting cells by a process known as transendocytosis¹⁶¹. Expression of CTLA4 by regulatory T (T_{reg}) cells is required to prevent fatal autoimmune disease in mice¹⁶², and T_{reg} cells can use CTLA4 to control the levels of CD80 and CD86 on dendritic cells trafficking from peripheral tissues to lymph nodes¹¹⁷. As the biological role of CTLA4 is to regulate the CD28 pathway, phenotypes associated with CTLA4 deficiency are lost in the absence of their shared ligands¹⁶³.

Follicular helper T (T_{FH}) cells are reciprocally regulated by CTLA4 and CD28. Mice lacking CTLA4 systemically or in T_{reg} cells exhibit exaggerated T_{FH} cell differentiation and this is recapitulated by injection of blocking anti-CTLA4 antibodies^{29,45,48} (see figure, part a). Humans with CTLA4 trafficking defects also exhibit increases in T_{FH} cell numbers³⁴. Conversely, soluble CTLA4 fusion proteins decrease T_{FH} cell numbers in mice and humans^{35,36,38}. Mice with wild-type CD28 expression have intact T_{FH} cell development, and those with lower CD28 expression due to *Cd28* gene heterozygosity show a reduced propensity for T_{FH} cell development, whereas complete CD28 deficiency abrogates T_{FH} cell development^{29,31} (see figure, part b).



PTPN2. *PTPN2* is a phosphatase involved in many signalling pathways, including IL-2 receptor signalling. T cell-specific deficiency in *Ptpn2* increased frequencies of T_{FH} cells and GC B cells in non-obese diabetic mice and was associated with exacerbated diabetes⁸⁸. It is likely that multiple pathways control IL-2 receptor signalling as defects are evident in T1D and MS even after controlling for *IL2RA* and *PTPN2* genotypes⁸⁹. Mice deficient in IL-2 or the IL-2 receptor subunits CD122 (IL-2R β) or CD25 (IL-2R α) develop lethal autoimmunity^{90–92} and mutations in IL-2R β cause life-threatening immune dysregulation in humans⁹³. Importantly, although IL-2 pathway genes can clearly modulate autoimmunity via effects on T_{reg} cell homeostasis, they can also act in

conventional T cells: for example, a SNP at the *IL2RA* locus associated with protection from T1D and MS was linked to higher levels of CD25 expression on conventional memory CD4⁺ T cells⁹⁴. Consistent with the role of the IL-2 pathway in the regulation of autoimmunity, low-dose IL-2 can be used therapeutically across a wide range of autoimmune diseases⁹⁵.


Collectively, these studies highlight the connection between control of T_{FH} cell differentiation and the genetic regulation of autoimmunity. Notably, genes in the CTLA4 and IL-2 pathways are consistently highlighted in genetic analyses across a broad range of common autoimmune conditions^{96,97}, and SNPs associated with autoimmunity are enriched in CpG demethylated regions specifically found in T_{reg} cells⁶².

This places CTLA4, IL-2 and T_{reg} cells at the heart of the shared genetic susceptibility to autoimmune disease that underpins heritability. Importantly, any defects in the CTLA4 or IL-2 pathways or deficits in T_{reg} cell homeostasis or function would lead to a dysregulated T_{FH} cell compartment as well as to the propensity to autoimmune disease (FIG. 3). This could be one reason for increases in cT_{FH} cells being seen across multiple autoimmune disease settings.


Infection as a link between T_{FH} cell differentiation and autoimmunity

The principal biological role for T_{FH} cells lies in protection from infectious disease. T_{FH} cell differentiation in response to viral, bacterial, parasitic or fungal antigens is key for the generation of protective antibody


a IL-2 promotes T_{reg} cell homeostasis



b IL-2 alters BLIMP1 to BCL-6 ratio



c CD25⁺ DCs act as IL-2 sink



d IL-6 downregulates IL-2R β -chain




Fig. 2 | IL-2-based inhibition of T_{FH} cells and adaptations to subvert this. **a** | IL-2 plays an important role in promoting FOXP3⁺ regulatory T (T_{reg}) cell homeostasis; T_{reg} cell-deficient mice⁴⁴ and humans⁴⁷ exhibit increased follicular helper T (T_{FH}) cell numbers. **b** | During T cell priming, IL-2-induced signalling through the IL-2 receptor (IL-2R) upregulates BLIMP1 expression, skewing the BLIMP1 to BCL-6 ratio and inhibiting T_{FH} cell differentiation^{74–77}. Transforming growth factor- β (TGF β) decreases IL-2R signalling by suppressing CD25 (IL-2R α) expression⁸⁰. **c** | CD25-expressing

dendritic cells (DCs) in the outer T cell zone can capture local IL-2, favouring T_{FH} cell differentiation⁸². **d** | Within the germinal centre (GC), IL-6 can desensitize IL-2R signalling in mature T_{FH} cells by downregulating the IL-2R subunit CD122 (IL-2R β)⁸³. APC, antigen-presenting cell; CTLA4, cytotoxic T lymphocyte antigen 4; CXCR5, CXC-chemokine receptor 5; FDC, follicular dendritic cell; ICOS, inducible T cell costimulator; ICOSL, ICOS ligand; PD1, programmed cell death protein 1; TCR, T cell receptor.




Fig. 3 | Common pathways control autoimmune susceptibility and T_H cell homeostasis. In healthy individuals, follicular helper T (T_{FH}) cell homeostasis is maintained by the CTLA4 pathway and regulatory T (T_{reg}) cells as well as by IL-2. Defects in the IL-2–IL-2R pathway can increase T_{FH} cell numbers, and single nucleotide polymorphisms (SNPs) in the IL-2 pathway are associated with autoimmune disease. Altered CTLA4 expression or trafficking (for example, owing to LRBA mutations) or defects in T_{reg} cells can increase T_{FH} cell numbers and are also associated with autoimmune disease susceptibility. CTLA4, cytotoxic T lymphocyte antigen 4; CXCR5, CXC-chemokine receptor 5; ICOS, inducible T cell costimulatory; PD1, programmed cell death protein 1; TCR, T cell receptor.

responses, in particular affinity-matured neutralizing antibodies⁹⁸. Mimicking infection by vaccination also induces T_{FH} cells, with transient increases in cT_{FH} cells being detectable in the blood⁹⁹.

Notably, infectious triggers have been postulated for many autoimmune diseases^{100–104}. Lyme disease is the quintessential example whereby immune responses to tick-borne *Borrelia burgdorferi* can give rise to Lyme arthritis with autoimmune T cell and B cell responses¹⁰⁵. In most of the common autoimmune diseases, a clear link to an individual pathogen is lacking; however, circumstantial evidence is often strong. For example, there is a known association between enteroviral infections and T1D¹⁰⁶, and enteroviral capsid protein¹⁰⁷ and an antiviral signature¹⁰⁸ have been detected in the pancreatic islets of people with T1D. Furthermore, recent data show a clear link between Epstein–Barr virus infection and the development of MS^{109,110}.

Persistent T_{FH} cells in chronic infection: helpers for autoreactive B cells? Although T_{FH} cell increases are short-lived in acute infection, chronic viral infections elicit persistent T_{FH} cell responses^{111,112}. Such increases in T_{FH} cells could interfere with competitive selection within the GC, potentially allowing the survival of self-reactive B cells. Indeed, persistent viral infection can elicit polyclonal B cell activation and production of autoantibodies¹¹³. In light

of this, it is interesting that prolonged enteroviral infection, rather than multiple short-duration infections, is associated with islet autoimmunity in T1D¹¹⁴.

The ability of self-reactive B cells to take up viral antigens, via pinocytosis, Fc receptors or complement receptors, may allow them to present viral peptides and solicit help from virus-specific T_{FH} cells¹¹³. In experimental systems, B cells specific for the central nervous system self-antigen myelin oligodendrocyte glycoprotein (MOG) can co-capture influenza virus haemagglutinin and MOG from cell membranes and obtain help from haemagglutinin-specific T cells to produce anti-MOG antibodies¹¹⁵. Interestingly, the ability of T_{FH} cells to provide help to bystander B cells and elicit autoantibody production appears to be enhanced by lymphopenia²⁰, a state long associated with autoimmunity. Conceivably, lymphopenia in the context of SARS-CoV-2 infection could contribute to the generation of autoantibodies documented in patients with COVID-19 (REF.¹¹⁶).

Potential for infection to unleash self-reactive T_{FH} cells. Chronic infections may alter T cell activation thresholds via the upregulation of costimulatory ligands in response to Toll-like receptor engagement or pro-inflammatory cytokines. This costimulatory ligand upregulation may outpace CTLA4-dependent ligand downregulation, permitting the activation of self-reactive T cells normally censored by

insufficient CD28 engagement¹¹⁷. Prolonged increases in T_{FH} cells could exacerbate this by increasing levels of IL-21, the archetypal T_{FH} cell-associated cytokine, which can counteract T_{reg} cell suppression^{118,119} and may reinforce T_{FH} cell differentiation¹²⁰. IL-21 is overexpressed in several autoimmune diseases, including SLE, RA, SS and T1D¹²¹, and although it can also derive from other cells, significant correlations between IL-21 production and T_{FH} cell frequencies have been noted^{122,123}. Thus, chronic infectious settings associated with elevated IL-21, blunted T_{reg} cell function and increased costimulation could permit self-reactive T cells to acquire a T_{FH} cell phenotype.

Infection may play a role in epitope spreading, which is a feature of many autoimmune diseases and is frequently associated with disease progression. One mechanism that may contribute to this phenomenon is the invasion and reuse of existing GCs by B cells bearing a different specificity, particularly in the context of shared T cell help (for example, when B cells specific for distinct regions of a protein interact with the same T_{FH} cell owing to presentation of a common peptide)¹²⁴. Cross-reactive recognition of bacterial antigens by self-reactive T cells could conceivably form the basis of shared T cell help in autoimmune settings¹²⁵. Notably, the presence of adjuvants, including the bacterial molecule lipopolysaccharide, can enhance GC invasion and reuse¹²⁴, suggesting that, in addition to unleashing new cohorts of T_{FH} cells, infection may also enhance the sharing of T cell help between B cells of different specificities.

The type 1 interferon connection. Infection and autoimmunity may also intersect mechanistically at involvement of the type 1 interferon pathway. Type 1 interferons provide the key ‘early warning’ signal of viral infection and play complex roles in protection or pathology following infection with viruses, bacteria, parasites and fungi¹²⁶. The type 1 interferon pathway has been widely associated with autoimmune diseases, most notably in the case of SLE but also in T1D, MS, RA and others^{127–130}. There are conflicting reports on the impact of type 1 interferons on T_{FH} cell differentiation. There is evidence that type 1 interferons promote acquisition of at least some aspects of the T_{FH} cell phenotype¹³¹, although other data suggest that they support T helper 1 cells at the expense of T_{FH} cells¹³². Studies focusing on DCs as the target cells for type 1 interferons point to a positive role in T_{FH} cell differentiation following immunization

or vaccination^{133,134} but a negative role in the setting of *Plasmodium* infection¹³⁵. As might be expected for the type 1 interferon pathway, timing, location and context are likely to be key in determining outcome¹³⁶.

Future directions


Different autoimmune diseases are highly distinct in their presentation, with unique tissue-specific features: for example, bone erosion in RA, renal pathology in SLE and metabolic abnormalities in T1D. Given the striking differences in disease processes and clinical presentation, it is remarkable that increases in cT_{FH} cells appear to be a unifying theme across a large number of autoimmune diseases. In this article, I highlight that CTLA4, IL-2 and T_{reg} cells are key modulators of T_{FH} cell differentiation and are also major players in the regulation of autoimmunity. This fundamental connection may go some way to explaining why dysregulated T_{FH} cell homeostasis is a feature of so many different autoimmune diseases. Reinforcing this connection, several other T_{FH} cell-associated genes (including *CXCR5*, *CCR7*, *ICOSL*, *PD1*, *ILAR*, *IL21R* and *CD40*) are linked to autoimmune disease susceptibility. The notion that genetic predisposition to autoimmunity may be coupled to genetic predisposition to T_{FH} cell formation provides a new perspective on the cT_{FH} cell changes widely reported in autoimmune settings.

As infection can lead to T_{FH} cell differentiation, it is conceivable that infectious triggers occurring on autoimmune-susceptible backgrounds may cause discernible changes to T_{FH} cell populations that precede autoimmunity. Thus, T_{FH} cells may represent the consummate biomarker in autoimmunity, neatly integrating genetic and environmental risk. Accordingly, T_{FH} cell profiling may be increasingly important in the prediction of autoimmune disease development and in monitoring and predicting clinical response to immunotherapies³⁸.

The precise contribution of T_{FH} cells, and their circulating counterparts, to pathology likely differs between autoimmune diseases. Dysregulated T_{FH} cell homeostasis may allow the production of autoantibodies that mediate diverse effector functions — for example, enhancing cross-presentation of islet antigens in T1D¹³⁷, driving renal pathology in SLE¹³⁸, and promoting osteoclastogenesis and bone loss in RA^{139,140}. As well as acting on B cells, the capacity for T_{FH} cells to produce IL-21 and CXCL13 (REF.⁸) may influence CD8⁺ T cell activation and ectopic lymphoid structure formation,

respectively, whereas dysregulated IFN γ production by T_{FH} cells¹⁴¹ has been shown to drive autoimmune GCs and systemic autoimmune disease¹⁴².

Altogether, closer study of T_{FH} cell populations in blood, lymphoid organs and tissues promises to yield new insight into autoimmune pathogenesis as well as allowing us to harness the full biomarker potential of this population.

Lucy S. K. Walker 

Institute of Immunity and Transplantation, University College London Division of Infection and Immunity, Royal Free Campus, London, UK.

e-mail: lucy.walker@ucl.ac.uk

<https://doi.org/10.1038/s41577-022-00693-5>

Published online 11 March 2022

- Victora, G. D. & Nussenzweig, M. C. Germinal centers. *Annu. Rev. Immunol.* **30**, 429–457 (2012).
- Vinuesa, C. G., Linterman, M. A., Yu, D. & MacLennan, I. C. Follicular helper T cells. *Annu. Rev. Immunol.* **34**, 335–368 (2016).
- Ueno, H., Banachereau, J. & Vinuesa, C. G. Pathophysiology of T follicular helper cells in humans and mice. *Nat. Immunol.* **16**, 142–152 (2015).
- Vinuesa, C. G. et al. A RING-type ubiquitin ligase family member required to repress follicular helper T cells and autoimmunity. *Nature* **435**, 452–458 (2005).
- Qi, H., Cannons, J. L., Klauschen, F., Schwartzberg, P. L. & Germain, R. N. SAP-controlled TB cell interactions underlie germinal centre formation. *Nature* **455**, 764–769 (2008).
- Linterman, M. A. et al. Follicular helper T cells are required for systemic autoimmunity. *J. Exp. Med.* **206**, 561–576 (2009).
- Simpson, N. et al. Expansion of circulating T cells resembling follicular helper T cells is a fixed phenotype that identifies a subset of severe systemic lupus erythematosus. *Arthritis Rheum.* **62**, 234–244 (2010).
- Ueno, H. T follicular helper cells in human autoimmunity. *Curr. Opin. Immunol.* **43**, 24–31 (2016).
- Morita, R. et al. Human blood CXCR5⁺CD4⁺ T cells are counterparts of T follicular cells and contain specific subsets that differentially support antibody secretion. *Immunity* **34**, 108–121 (2011).
- Weber, J. P., Fuhrmann, F. & Hutloff, A. T follicular helper cells survive as long-term memory cells. *Eur. J. Immunol.* **42**, 1981–1988 (2012).
- Choi, Y. S. et al. Bcl6 expressing follicular helper CD4 T cells are fate committed early and have the capacity to form memory. *J. Immunol.* **190**, 4014–4026 (2013).
- Hale, J. S. et al. Distinct memory CD4⁺ T cells with commitment to T follicular helper- and T helper 1-cell lineages are generated after acute viral infection. *Immunity* **38**, 805–817 (2013).
- Locci, M. et al. Human circulating PD-1⁺CXCR3⁺CXCR5⁺ memory Tfh cells are highly functional and correlate with broadly neutralizing HIV antibody responses. *Immunity* **39**, 758–769 (2013).
- Schmitt, N., Benteibibel, S. E. & Ueno, H. Phenotype and functions of memory Tfh cells in human blood. *Trends Immunol.* **35**, 436–442 (2014).
- Bossaller, L. et al. ICOS deficiency is associated with a severe reduction of CXCR5⁺CD4⁺ germinal center T cells. *J. Immunol.* **177**, 4927–4932 (2006).
- Ma, C. S. et al. Monogenic mutations differentially affect the quantity and quality of T follicular helper cells in patients with human primary immunodeficiencies. *J. Allergy Clin. Immunol.* **136**, 993–1006.e1 (2015).
- Kitano, M. et al. Bcl6 protein expression shapes pre-germinal center B cell dynamics and follicular helper T cell heterogeneity. *Immunity* **34**, 961–972 (2011).
- Sage, P. T., Alvarez, D., Godec, J., von Andrian, U. H. & Sharpe, A. H. Circulating T follicular regulatory and helper cells have memory-like properties. *J. Clin. Invest.* **124**, 5191–5204 (2014).
- Asrir, A., Aloulou, M., Gador, M., Peralas, C. & Fazilleau, N. Interconnected subsets of memory follicular helper T cells have different effector functions. *Nat. Commun.* **8**, 847 (2017).
- Baumjohann, D. et al. Persistent antigen and germinal center B cells sustain T follicular helper cell responses and phenotype. *Immunity* **38**, 596–605 (2013).
- Shulman, Z. et al. T follicular helper cell dynamics in germinal centers. *Science* **341**, 673–677 (2013).
- He, J. et al. Circulating precursor CCR7⁺PD-1^{hi} CXCR5⁺CD4⁺ T cells indicate Tfh cell activity and promote antibody responses upon antigen reexposure. *Immunity* **39**, 770–781 (2013).
- Wong, M. T. et al. Mapping the diversity of follicular helper T cells in human blood and tonsils using high-dimensional mass cytometry analysis. *Cell Rep.* **11**, 1822–1833 (2015).
- Heit, A. et al. Vaccination establishes clonal relatives of germinal center T cells in the blood of humans. *J. Exp. Med.* **214**, 2139–2152 (2017).
- Hill, D. L. et al. The adjuvant GLA-SE promotes human Tfh cell expansion and emergence of public TCRbeta clonotypes. *J. Exp. Med.* **216**, 1857–1873 (2019).
- Vella, L. A. et al. T follicular helper cells in human efferent lymph retain lymphoid characteristics. *J. Clin. Invest.* **129**, 3185–3200 (2019).
- Huber, J. E. et al. Fingolimod profoundly reduces frequencies and alters subset composition of circulating T follicular helper cells in multiple sclerosis patients. *J. Immunol.* **204**, 1101–1110 (2020).
- Wardemann, H. et al. Predominant autoantibody production by early human B cell precursors. *Science* **301**, 1374–1377 (2003).
- Wang, C. J. et al. CTLA-4 controls follicular helper T cell differentiation by regulating the strength of CD28 engagement. *Proc. Natl Acad. Sci. USA* **112**, 524–529 (2015).
- Ferguson, S. E., Han, S., Kelsoe, G. & Thompson, C. B. CD28 is required for germinal center formation. *J. Immunol.* **156**, 4576–4581 (1996).
- Walker, L. S. et al. Compromised OX40 function in CD28-deficient mice is linked with failure to develop CXCR5⁺CD4⁺ cells and germinal centers. *J. Exp. Med.* **190**, 1115–1122 (1999).
- Rolf, J. et al. Phosphoinositide 3-kinase activity in T cells regulates the magnitude of the germinal center reaction. *J. Immunol.* **185**, 4042–4052 (2010).
- Baumjohann, D. et al. The microRNA cluster miR-17 approximately 92 promotes TFH cell differentiation and represses subset-inappropriate gene expression. *Nat. Immunol.* **14**, 840–848 (2013).
- Alroqi, F. J. et al. Exaggerated follicular helper T-cell responses in patients with LRBA deficiency caused by failure of CTLA4-mediated regulation. *J. Allergy Clin. Immunol.* **141**, 1050–1059.e10 (2018).
- Verstappen, G. M. et al. Attenuation of follicular helper T cell-dependent B cell hyperactivity by abatacept treatment in primary Sjogren's syndrome. *Arthritis Rheumatol.* **69**, 1850–1861 (2017).
- Piantoni, S., Regola, F., Scarsi, M., Tincani, A. & Airo, P. Circulating follicular helper T cells (CD4⁺CXCR5⁺ICOS⁺) decrease in patients with rheumatoid arthritis treated with abatacept. *Clin. Exp. Rheumatol.* **36**, 685 (2018).
- Glatigny, S. et al. Abatacept targets T follicular helper and regulatory T cells, disrupting molecular pathways that regulate their proliferation and maintenance. *J. Immunol.* **202**, 1373–1382 (2019).
- Edner, N. M. et al. Follicular helper T cell profiles predict response to costimulation blockade in type 1 diabetes. *Nat. Immunol.* **21**, 1244–1255 (2020).
- Tivol, E. A. et al. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. *Immunity* **3**, 541–547 (1995).
- Waterhouse, P. et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. *Science* **270**, 985–988 (1995).
- Schubert, D. et al. Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations. *Nat. Med.* **20**, 1410–1416 (2014).
- Kuehn, H. S. et al. Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4. *Science* **345**, 1623–1627 (2014).
- Lo, B. et al. Patients with LRBA deficiency show CTLA4 loss and immune dysregulation responsive to abatacept therapy. *Science* **349**, 436–440 (2015).
- Chung, Y. et al. Follicular regulatory T cells expressing Foxp3 and Bcl-6 suppress germinal center reactions. *Nat. Med.* **17**, 983–988 (2011).
- Wing, J. B., Ise, W., Kurosaki, T. & Sakaguchi, S. Regulatory T cells control antigen-specific expansion of Tfh cell number and humoral immune responses via the coreceptor CTLA-4. *Immunity* **41**, 1013–1025 (2014).

46. Linterman, M. A. et al. Foxp3⁺ follicular regulatory T cells control the germinal center response. *Nat. Med.* **17**, 975–982 (2011).
47. Kinnunen, T. et al. Accumulation of peripheral autoreactive B cells in the absence of functional human regulatory T cells. *Blood* **121**, 1595–1603 (2013).
48. Sage, P. T., Paterson, A. M., Lovitch, S. B. & Sharpe, A. H. The coinhibitory receptor CTLA-4 controls B cell responses by modulating T follicular helper, T follicular regulatory, and T regulatory cells. *Immunity* **41**, 1026–1039 (2014).
49. Wollenberg, I. et al. Regulation of the germinal center reaction by Foxp3⁺ follicular regulatory T cells. *J. Immunol.* **187**, 4553–4560 (2011).
50. Botta, D. et al. Dynamic regulation of T follicular regulatory cell responses by interleukin 2 during influenza infection. *Nat. Immunol.* **18**, 1249–1260 (2017).
51. Ritvo, P. G. et al. Tfr cells lack IL-2Ralpha but express decoy IL-1R2 and IL-1Ra and suppress the IL-1-dependent activation of Tfh cells. *Sci. Immunol.* **2**, ea0368 (2017).
52. Fu, W. et al. Deficiency in T follicular regulatory cells promotes autoimmunity. *J. Exp. Med.* **215**, 815–825 (2018).
53. Clement, R. L. et al. Follicular regulatory T cells control humoral and allergic immunity by restraining early B cell responses. *Nat. Immunol.* **20**, 1360–1371 (2019).
54. Lu, Y. et al. CD4⁺ follicular regulatory T cells optimize the influenza virus-specific B cell response. *J. Exp. Med.* **218**, e20200547 (2021).
55. Wing, J. B., Tekguc, M. & Sakaguchi, S. Control of germinal center responses by T-follicular regulatory cells. *Front. Immunol.* **9**, 1910 (2018).
56. Deng, J., Wei, Y., Fonseca, V. R., Graca, L. & Yu, D. T follicular helper cells and T follicular regulatory cells in rheumatic diseases. *Nat. Rev. Rheumatol.* **15**, 475–490 (2019).
57. Gonzalez-Figueroa, P. et al. Follicular regulatory T cells produce neuritin to regulate B cells. *Cell* **184**, 1775–1789.e19 (2021).
58. Wu, H. et al. Follicular regulatory T cells repress cytokine production by follicular helper T cells and optimize IgG responses in mice. *Eur. J. Immunol.* **46**, 1152–1161 (2016).
59. Sage, P. T. et al. Suppression by TFR cells leads to durable and selective inhibition of B cell effector function. *Nat. Immunol.* **17**, 1436–1446 (2016).
60. Jacobsen, J. T. et al. Expression of Foxp3 by T follicular helper cells in end-stage germinal centers. *Science* **373**, eabe5146 (2021).
61. Wing, J. B. et al. A distinct subpopulation of CD25(+) T-follicular regulatory cells localizes in the germinal centers. *Proc. Natl Acad. Sci. USA* **114**, E6400–E6409 (2017).
62. Ohkura, N. et al. Regulatory T cell-specific epigenomic region variants are a key determinant of susceptibility to common autoimmune diseases. *Immunity* **52**, 1119–1132.e4 (2020).
63. Brunkow, M. E. et al. Disruption of a new forkhead/winged-helix protein, scurfy, results in the fatal lymphoproliferative disorder of the scurfy mouse. *Nat. Genet.* **27**, 68–73 (2001).
64. Wildin, R. S., Smyk-Pearson, S. & Filipovich, A. H. Clinical and molecular features of the immunodysregulation, polyendocrinopathy, enteropathy, X linked (IPEX) syndrome. *J. Med. Genet.* **39**, 537–545 (2002).
65. Salomon, B. et al. B7/CD28 costimulation is essential for the homeostasis of the CD4⁺CD25⁺ immunoregulatory T cells that control autoimmune diabetes. *Immunity* **12**, 431–440 (2000).
66. Beziat, V. et al. Humans with inherited T cell CD28 deficiency are susceptible to skin papillomaviruses but are otherwise healthy. *Cell* **184**, 3812–3828 (2021).
67. Ballesteros-Tato, A. et al. Interleukin-2 inhibits germinal center formation by limiting T follicular helper cell differentiation. *Immunity* **36**, 847–856 (2012).
68. Ward, N. C. et al. Persistent IL-2 receptor signaling by IL-2/CD25 fusion protein controls diabetes in NOD mice by multiple mechanisms. *Diabetes* **69**, 2400–2413 (2020).
69. Locci, M. et al. Activin A programs the differentiation of human TFH cells. *Nat. Immunol.* **17**, 976–984 (2016).
70. He, J. et al. Low-dose interleukin-2 treatment selectively modulates CD4⁺ T cell subsets in patients with systemic lupus erythematosus. *Nat. Med.* **22**, 991–993 (2016).
71. Setoguchi, R., Hori, S., Takahashi, T. & Sakaguchi, S. Homeostatic maintenance of natural Foxp3⁺ CD25⁺ CD4⁺ regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization. *J. Exp. Med.* **201**, 723–735 (2005).
72. Fontenot, J. D., Rasmussen, J. P., Gavin, M. A. & Rudensky, A. Y. A function for interleukin 2 in Foxp3-expressing regulatory T cells. *Nat. Immunol.* **6**, 1142–1151 (2005).
73. Webster, K. E. et al. In vivo expansion of T reg cells with IL-2-mAb complexes: induction of resistance to EAE and long-term acceptance of islet allografts without immunosuppression. *J. Exp. Med.* **206**, 751–760 (2009).
74. Choi, Y. S. et al. ICOS receptor instructs T follicular helper cell versus effector cell differentiation via induction of the transcriptional repressor Bcl6. *Immunity* **34**, 932–946 (2011).
75. Pepper, M., Pagan, A. J., Igyarto, B. Z., Taylor, J. J. & Jenkins, M. K. Opposing signals from the Bcl6 transcription factor and the interleukin-2 receptor generate T helper 1 central and effector memory cells. *Immunity* **35**, 583–595 (2011).
76. Johnston, R. J., Choi, Y. S., Diamond, J. A., Yang, J. A. & Crotty, S. STAT5 is a potent negative regulator of TFH cell differentiation. *J. Exp. Med.* **209**, 243–250 (2012).
77. Nurieva, R. I. et al. STAT5 protein negatively regulates T follicular helper (Tfh) cell generation and function. *J. Biol. Chem.* **287**, 11234–11239 (2012).
78. DiToro, D. et al. Differential IL-2 expression defines developmental fates of follicular versus nonfollicular helper T cells. *Science* **361**, ea02933 (2018).
79. Sabatos, C. A. et al. A synaptic basis for paracrine interleukin-2 signaling during homotypic T cell interaction. *Immunity* **29**, 238–248 (2008).
80. Marshall, H. D. et al. The transforming growth factor beta signaling pathway is critical for the formation of CD4⁺ T follicular helper cells and isotype-switched antibody responses in the lung mucosa. *eLife* **4**, e04851 (2015).
81. Schmitt, N. et al. The cytokine TGF-beta co-opts signaling via STAT3-STAT4 to promote the differentiation of human TFH cells. *Nat. Immunol.* **15**, 856–865 (2014).
82. Li, J., Lu, E., Yi, T. & Cyster, J. G. EB12 augments Tfh cell fate by promoting interaction with IL-2-quenching dendritic cells. *Nature* **533**, 110–114 (2016).
83. Papillon, A. et al. Inhibition of IL-2 responsiveness by IL-6 is required for the generation of GC-TFH cells. *Sci. Immunol.* **4**, eaaw7636 (2019).
84. Oestreich, K. J., Mohn, S. E. & Weinmann, A. S. Molecular mechanisms that control the expression and activity of Bcl-6 in TH1 cells to regulate flexibility with a TFH-like gene profile. *Nat. Immunol.* **13**, 405–411 (2012).
85. Pandiyan, P., Zheng, L., Ishihara, S., Reed, J. & Lenardo, M. J. CD4⁺CD25⁺Foxp3⁺ regulatory T cells induce cytokine deprivation-mediated apoptosis of effector CD4⁺ T cells. *Nat. Immunol.* **8**, 1353–1362 (2007).
86. Chinen, T. et al. An essential role for the IL-2 receptor in Treg cell function. *Nat. Immunol.* **17**, 1322–1333 (2016).
87. Lowe, C. E. et al. Large-scale genetic fine mapping and genotype-phenotype associations implicate polymorphism in the IL2RA region in type 1 diabetes. *Nat. Genet.* **39**, 1074–1082 (2007).
88. Wiede, F. et al. T-cell-specific PTPN22 deficiency in NOD mice accelerates the development of type 1 diabetes and autoimmune comorbidities. *Diabetes* **68**, 1251–1266 (2019).
89. Cerosaletti, K. et al. Multiple autoimmune-associated variants confer decreased IL-2R signaling in CD4⁺ CD25^{hi} T cells of type 1 diabetic and multiple sclerosis patients. *PLoS One* **8**, e83811 (2013).
90. Sadlack, B. et al. Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. *Cell* **75**, 253–261 (1993).
91. Suzuki, H. et al. Deregulated T cell activation and autoimmunity in mice lacking interleukin-2 receptor beta. *Science* **268**, 1472–1476 (1995).
92. Willerford, D. M. et al. Interleukin-2 receptor alpha chain regulates the size and content of the peripheral lymphoid compartment. *Immunity* **3**, 521–530 (1995).
93. Zhang, Z. et al. Human interleukin-2 receptor beta mutations associated with defects in immunity and peripheral tolerance. *J. Exp. Med.* **216**, 1311–1327 (2019).
94. Dendrou, C. A. et al. Cell-specific protein phenotypes for the autoimmune locus IL2RA using a genotype-selectable human bioresource. *Nat. Genet.* **41**, 1011–1015 (2009).
95. Rosenzweig, M. et al. Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial. *Ann. Rheum. Dis.* **78**, 209–217 (2019).
96. Farh, K. K. et al. Genetic and epigenetic fine mapping of causal autoimmune disease variants. *Nature* **518**, 337–343 (2015).
97. Cotsapas, C. et al. Pervasive sharing of genetic effects in autoimmune disease. *PLoS Genet.* **7**, e1002254 (2011).
98. Crotty, S. T follicular helper cell biology: a decade of discovery and diseases. *Immunity* **50**, 1132–1148 (2019).
99. Bentebibel, S. E. et al. Induction of ICOS⁺CXCR3⁺CXCR5⁺ TH cells correlates with antibody responses to influenza vaccination. *Sci. Transl. Med.* **5**, 176ra132 (2013).
100. Qiu, C. C., Caricchio, R. & Gallucci, S. Triggers of autoimmunity: the role of bacterial infections in the extracellular exposure of lupus nuclear autoantigens. *Front. Immunol.* **10**, 2608 (2019).
101. Van Ghelue, M., Moens, U., Bendiksen, S. & Rekvig, O. P. Autoimmunity to nucleosomes related to viral infection: a focus on hapten-carrier complex formation. *J. Autoimmun.* **20**, 171–182 (2005).
102. Rodriguez-Calvo, T. Enteroviral infections as a trigger for type 1 diabetes. *Curr. Diab Rep.* **18**, 106 (2018).
103. Konig, M. F. et al. Aggregatibacter actinomycetemcomitans-induced hypercitrullination links periodontal infection to autoimmunity in rheumatoid arthritis. *Sci. Transl. Med.* **8**, 369ra176 (2016).
104. Steelman, A. J. Infection as an environmental trigger of multiple sclerosis disease exacerbation. *Front. Immunol.* **6**, 520 (2015).
105. Lochhead, R. B., Strle, K., Arvikar, S. L., Weis, J. J. & Steere, A. C. Lyme arthritis: linking infection, inflammation and autoimmunity. *Nat. Rev. Rheumatol.* **17**, 449–461 (2021).
106. Wang, K. et al. Association between enterovirus infection and type 1 diabetes risk: a meta-analysis of 38 case-control studies. *Front. Endocrinol.* **12**, 706964 (2021).
107. Richardson, S. J., Leete, P., Bone, A. J., Foulis, A. K. & Morgan, N. G. Expression of the enteroviral capsid protein VP1 in the islet cells of patients with type 1 diabetes is associated with induction of protein kinase R and downregulation of Mcl-1. *Diabetologia* **56**, 185–193 (2013).
108. Apaolaza, P. S. et al. Islet expression of type I interferon response sensors is associated with immune infiltration and viral infection in type 1 diabetes. *Sci. Adv.* **7**, eabd6527 (2021).
109. Bjornevik, K. et al. Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis. *Science* **375**, 296–301 (2022).
110. Lanz, T. V. et al. Clonally expanded B cells in multiple sclerosis bind EBV EBNA1 and GlialCAM. *Nature* <https://doi.org/10.1038/s41586-022-04432-7> (2022).
111. Greczmiel, U. et al. Sustained T follicular helper cell response is essential for control of chronic viral infection. *Sci. Immunol.* **2**, eaam8686 (2017).
112. Fahey, L. M. et al. Viral persistence redirects CD4 T cell differentiation toward T follicular helper cells. *J. Exp. Med.* **208**, 987–999 (2011).
113. Hunziker, L. et al. Hypergammaglobulinemia and autoantibody induction mechanisms in viral infections. *Nat. Immunol.* **4**, 343–349 (2003).
114. Vehik, K. et al. Prospective virome analyses in young children at increased genetic risk for type 1 diabetes. *Nat. Med.* **25**, 1865–1872 (2019).
115. Sanderson, N. S. et al. Cocapture of cognate and bystander antigens can activate autoreactive B cells. *Proc. Natl Acad. Sci. USA* **114**, 734–739 (2017).
116. Wang, E. Y. et al. Diverse functional autoantibodies in patients with COVID-19. *Nature* **595**, 283–288 (2021).
117. Ovcinnikovs, V. et al. CTLA-4-mediated transendocytosis of costimulatory molecules primarily targets migratory dendritic cells. *Sci. Immunol.* **4**, eaaw0902 (2019).
118. Peluso, I. et al. IL-21 counteracts the regulatory T cell-mediated suppression of human CD4⁺ T lymphocytes. *J. Immunol.* **178**, 732–739 (2007).
119. Clough, L. E. et al. Release from regulatory T cell-mediated suppression during the onset of tissue-specific autoimmunity is associated with elevated IL-21. *J. Immunol.* **180**, 5393–5401 (2008).
120. Vogelzang, A. et al. A fundamental role for interleukin-21 in the generation of T follicular helper cells. *Immunity* **29**, 127–137 (2008).

121. Spolski, R. & Leonard, W. J. Interleukin-21: a double-edged sword with therapeutic potential. *Nat. Rev. Drug Discov.* **13**, 379–395 (2014).
122. Kenefeck, R. et al. Follicular helper T cell signature in type 1 diabetes. *J. Clin. Invest.* **125**, 292–303 (2015).
123. Ferreira, R. C. et al. IL-21 production by CD4 effector T cells and frequency of circulating follicular helper T cells are increased in type 1 diabetes patients. *Diabetologia* **58**, 781–790 (2015).
124. Schwickert, T. A., Alabyev, B., Manser, T. & Nussenzweig, M. C. Germinal center reutilization by newly activated B cells. *J. Exp. Med.* **206**, 2907–2914 (2009).
125. Zhao, Z. et al. Nature of T cell epitopes in lupus antigens and HLA-DR determines autoantibody initiation and diversification. *Ann. Rheum. Dis.* **78**, 380–390 (2019).
126. McNab, F., Mayer-Barber, K., Sher, A., Wack, A. & O'Garra, A. Type I interferons in infectious disease. *Nat. Rev. Immunol.* **15**, 87–103 (2015).
127. Bennett, L. et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. *J. Exp. Med.* **197**, 711–723 (2003).
128. Hall, J. C. & Rosen, A. Type I interferons: crucial participants in disease amplification in autoimmunity. *Nat. Rev. Rheumatol.* **6**, 40–49 (2010).
129. Ferreira, R. C. et al. A type I interferon transcriptional signature precedes autoimmunity in children genetically at risk for type 1 diabetes. *Diabetes* **63**, 2538–2550 (2014).
130. van Baarsen, L. G. et al. A subtype of multiple sclerosis defined by an activated immune defense program. *Genes Immun.* **7**, 522–531 (2006).
131. Nakayama, S. et al. Type I IFN induces binding of STAT1 to Bcl6: divergent roles of STAT family transcription factors in the T follicular helper cell genetic program. *J. Immunol.* **192**, 2156–2166 (2014).
132. Ray, J. P. et al. Transcription factor STAT3 and type I interferons are corepressive insulators for differentiation of follicular helper and T helper 1 cells. *Immunity* **40**, 367–377 (2014).
133. Cucak, H., Yrlid, U., Reizis, B., Kalinke, U. & Johansson-Lindbom, B. Type I interferon signaling in dendritic cells stimulates the development of lymph-node-resident T follicular helper cells. *Immunity* **31**, 491–501 (2009).
134. Stebbins, M. et al. Rejuvenating conventional dendritic cells and T follicular helper cell formation after vaccination. *eLife* **9**, e52473 (2020).
135. Sebina, I. et al. IFNAR1-signalling obstructs ICOS-mediated humoral immunity during non-lethal blood-stage plasmodium infection. *PLoS Pathog.* **12**, e1005999 (2016).
136. De Giovanni, M. et al. Spatiotemporal regulation of type I interferon expression determines the antiviral polarization of CD4⁺ T cells. *Nat. Immunol.* **21**, 321–330 (2020).
137. Harbers, S. O. et al. Antibody-enhanced cross-presentation of self antigen breaks T cell tolerance. *J. Clin. Invest.* **117**, 1361–1369 (2007).
138. Suurmond, J. & Diamond, B. Autoantibodies in systemic autoimmune diseases: specificity and pathogenicity. *J. Clin. Invest.* **125**, 2194–2202 (2015).
139. Harre, U. et al. Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin. *J. Clin. Invest.* **122**, 1791–1802 (2012).
140. Engdahl, C. et al. Periarticular bone loss in arthritis is induced by autoantibodies against citrullinated vimentin. *J. Bone Miner. Res.* **32**, 1681–1691 (2017).
141. Faliti, C. E. et al. P2X7 receptor restrains pathogenic Tfh cell generation in systemic lupus erythematosus. *J. Exp. Med.* **216**, 317–336 (2019).
142. Jackson, S. W. et al. B cell IFN-gamma receptor signaling promotes autoimmune germinal centers via cell-intrinsic induction of BCL-6. *J. Exp. Med.* **213**, 733–750 (2016).
143. Yu, D. et al. The transcriptional repressor Bcl-6 directs T follicular helper cell lineage commitment. *Immunity* **31**, 457–468 (2009).
144. Johnston, R. J. et al. Bcl6 and Blimp-1 are reciprocal and antagonistic regulators of T follicular helper cell differentiation. *Science* **325**, 1006–1010 (2009).
145. Nurieva, R. I. et al. Bcl6 mediates the development of T follicular helper cells. *Science* **325**, 1001–1005 (2009).
146. Choi, J. et al. Bcl-6 is the nexus transcription factor of T follicular helper cells via repressor-of-repressor circuits. *Nat. Immunol.* **21**, 777–789 (2020).
147. Bauquet, A. T. et al. The costimulatory molecule ICOS regulates the expression of c-Maf and IL-21 in the development of follicular T helper cells and TH-17 cells. *Nat. Immunol.* **10**, 167–175 (2009).
148. Betz, B. C. et al. Batf coordinates multiple aspects of B and T cell function required for normal antibody responses. *J. Exp. Med.* **207**, 935–942 (2010).
149. Ise, W. et al. The transcription factor BATF controls the global regulators of class-switch recombination in both B cells and T cells. *Nat. Immunol.* **12**, 536–543 (2011).
150. Liu, X. et al. Transcription factor achaete-scute homologue 2 initiates follicular T-helper-cell development. *Nature* **507**, 513–518 (2014).
151. Weber, J. P. et al. ICOS maintains the T follicular helper cell phenotype by down-regulating Kruppel-like factor 2. *J. Exp. Med.* **212**, 217–233 (2015).
152. Ma, C. S. et al. Functional STAT3 deficiency compromises the generation of human T follicular helper cells. *Blood* **119**, 3997–4008 (2012).
153. Choi, Y. S., Eto, D., Yang, J. A., Lao, C. & Crotty, S. Cutting edge: STAT1 is required for IL-6-mediated Bcl6 induction for early follicular helper cell differentiation. *J. Immunol.* **190**, 3049–3053 (2013).
154. Okada, T. et al. Antigen-engaged B cells undergo chemotaxis toward the T zone and form motile conjugates with helper T cells. *PLoS Biol.* **3**, e150 (2005).
155. Schwickert, T. A. et al. A dynamic T cell-limited checkpoint regulates affinity-dependent B cell entry into the germinal center. *J. Exp. Med.* **208**, 1243–1252 (2011).
156. Bentebibel, S. E., Schmitt, N., Banchereau, J. & Ueno, H. Human tonsil B-cell lymphoma 6 (BCL6)-expressing CD4⁺ T-cell subset specialized for B-cell help outside germinal centers. *Proc. Natl Acad. Sci. USA* **108**, E488–E497 (2011).
157. Odegard, J. M. et al. ICOS-dependent extrafollicular helper T cells elicit IgG production via IL-21 in systemic autoimmunity. *J. Exp. Med.* **205**, 2873–2886 (2008).
158. Liu, B. et al. Affinity-coupled CCL22 promotes positive selection in germinal centres. *Nature* **592**, 133–137 (2021).
159. Dan, J. M. et al. A cytokine-independent approach to identify antigen-specific human germinal center T follicular helper cells and rare antigen-specific CD4⁺ T cells in blood. *J. Immunol.* **197**, 983–993 (2016).
160. Collins, A. V. et al. The interaction properties of costimulatory molecules revisited. *Immunity* **17**, 201–210 (2002).
161. Qureshi, O. S. et al. Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4. *Science* **332**, 600–603 (2011).
162. Wing, K. et al. CTLA-4 control over Foxp3⁺ regulatory T cell function. *Science* **322**, 271–275 (2008).
163. Mandelbrot, D. A., McAdam, A. J. & Sharpe, A. H. B7-1 or B7-2 is required to produce the lymphoproliferative phenotype in mice lacking cytotoxic T lymphocyte-associated antigen 4 (CTLA-4). *J. Exp. Med.* **189**, 435–440 (1999).
164. Fonseca, V. R. et al. Human blood Tfr cells are indicators of ongoing humoral activity not fully licensed with suppressive function. *Sci. Immunol.* **2**, ean148 (2017).

Acknowledgements

I am grateful to M. A. Linterman, P. Tolar, N. M. Edner, C. J. Wang and L. Petersone for valuable feedback on the manuscript draft and for assistance with the figures. I am supported by a Medical Research Council Programme Grant and a Wellcome Trust Investigator Award.

Competing interests

The author is an inventor on a patent relating to T_{fh} cell profiles and predicting response to costimulation blockade in autoimmunity.

Peer review information

Nature Reviews Immunology thanks the anonymous reviewers for their contribution to the peer review of this work.

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

RELATED LINKS

GWAS Catalogue: <https://www.ebi.ac.uk/gwas>

© Springer Nature Limited 2022